Extended-release buprenorphine not cost-effective when transmucosal buprenorphine is available for treatment of OUD
Likelihood of experiencing a serious medical outcome or being admitted to a health care facility was increased for children younger than 6 years
Combination of a patch and fast-acting nicotine replacement therapy also effective
Among patients with ADRD receiving care from a home health agency, antipsychotic use was tied to less improvement in activities of daily living
Comparable rates of in-hospital adverse events seen among seniors prescribed oral antipsychotics after major surgery
Considerable impact scores reported in physical, psychological, social domains; professional lives also affected
Medications for OUD more likely for those with severe versus mild past-year OUD, receiving substance use treatment via telehealth
Significant improvement seen in 17-item Hamilton Depression Rating Scale, Clinical Global Impressions severity score
Improvement seen in measures of sleepiness, cataplexy over eight weeks versus placebo, but drug was associated with hepatotoxic effects
Pfizer is working to repair the damage and mitigate any shortage of drugs made at the facility